EGFR and non-small cell lung carcinoma: In conclusion, the combination of EGFR TKI with gefitinib and anti-angiogenic therapy with anlotinib significantly improved PFS with a manageable safety profile for patients with untreated advanced NSCLC harboring EGFR activating mutations.